AU730228B2 - Propanolamine derivatives, processes for their preparation, pharmaceuticals comprising these compounds, and their use - Google Patents

Propanolamine derivatives, processes for their preparation, pharmaceuticals comprising these compounds, and their use Download PDF

Info

Publication number
AU730228B2
AU730228B2 AU60624/98A AU6062498A AU730228B2 AU 730228 B2 AU730228 B2 AU 730228B2 AU 60624/98 A AU60624/98 A AU 60624/98A AU 6062498 A AU6062498 A AU 6062498A AU 730228 B2 AU730228 B2 AU 730228B2
Authority
AU
Australia
Prior art keywords
alkyl
formula
compound
fluorine
rac
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU60624/98A
Other languages
English (en)
Other versions
AU6062498A (en
Inventor
Karl-Heinz Baringhaus
Alfons Ehnsen
Heiner Glombik
Werner Kramer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Hoechst Marion Roussel Deutschland GmbH
Hoechst Marion Roussel Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE1998102530 external-priority patent/DE19802530A1/de
Application filed by Hoechst Marion Roussel Deutschland GmbH, Hoechst Marion Roussel Inc filed Critical Hoechst Marion Roussel Deutschland GmbH
Publication of AU6062498A publication Critical patent/AU6062498A/en
Priority to AU61925/99A priority Critical patent/AU760412B2/en
Application granted granted Critical
Publication of AU730228B2 publication Critical patent/AU730228B2/en
Assigned to AVENTIS PHARMA DEUTSCHLAND GMBH reassignment AVENTIS PHARMA DEUTSCHLAND GMBH Amend patent request/document other than specification (104) Assignors: HOECHST MARION ROUSSEL DEUTSCHLAND GMBH
Assigned to SANOFI-AVENTIS DEUTSCHLAND GMBH reassignment SANOFI-AVENTIS DEUTSCHLAND GMBH Request to Amend Deed and Register Assignors: AVENTIS PHARMA DEUTSCHLAND GMBH
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Obesity (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
AU60624/98A 1997-04-04 1998-04-03 Propanolamine derivatives, processes for their preparation, pharmaceuticals comprising these compounds, and their use Ceased AU730228B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU61925/99A AU760412B2 (en) 1997-04-04 1999-09-18 Propanolamine derivatives substituted with heterocyclic compounds, methods for their production, pharmaceutical compositions containing said compounds and the use thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE19713865 1997-04-04
DE19713865 1997-04-04
DE1998102530 DE19802530A1 (de) 1998-01-26 1998-01-26 Propanolaminderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DE19802530 1998-01-26

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU61925/99A Division AU760412B2 (en) 1997-04-04 1999-09-18 Propanolamine derivatives substituted with heterocyclic compounds, methods for their production, pharmaceutical compositions containing said compounds and the use thereof

Publications (2)

Publication Number Publication Date
AU6062498A AU6062498A (en) 1998-10-08
AU730228B2 true AU730228B2 (en) 2001-03-01

Family

ID=26035472

Family Applications (1)

Application Number Title Priority Date Filing Date
AU60624/98A Ceased AU730228B2 (en) 1997-04-04 1998-04-03 Propanolamine derivatives, processes for their preparation, pharmaceuticals comprising these compounds, and their use

Country Status (23)

Country Link
US (1) US5874451A (enExample)
EP (1) EP0869121B1 (enExample)
JP (1) JP4234805B2 (enExample)
KR (1) KR19980081055A (enExample)
CN (1) CN1185217C (enExample)
AR (1) AR011210A1 (enExample)
AT (1) ATE268758T1 (enExample)
AU (1) AU730228B2 (enExample)
BR (1) BR9801150A (enExample)
CA (1) CA2233925A1 (enExample)
CZ (1) CZ293758B6 (enExample)
DE (1) DE59811528D1 (enExample)
DK (1) DK0869121T3 (enExample)
ES (1) ES2223091T3 (enExample)
HU (1) HUP9800781A3 (enExample)
ID (1) ID20137A (enExample)
IL (1) IL123927A (enExample)
MY (1) MY114944A (enExample)
NZ (1) NZ330110A (enExample)
PL (1) PL325699A1 (enExample)
PT (1) PT869121E (enExample)
RU (1) RU2198876C2 (enExample)
TR (1) TR199800608A3 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19845402B4 (de) 1998-10-02 2005-04-07 Aventis Pharma Deutschland Gmbh Mit Heterocyclen substituierte Propanolaminderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DE69919707T2 (de) 1998-06-19 2005-09-01 Chiron Corp., Emeryville Glycogen synthase kinase 3 inhibitoren
US7045519B2 (en) * 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
DE19845403B4 (de) 1998-10-02 2005-02-10 Aventis Pharma Deutschland Gmbh Mit Gallensäuren verknüpfte Propanolaminderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DE19845406C2 (de) * 1998-10-02 2001-10-18 Aventis Pharma Gmbh Substituierte 1,3-Diaryl-2-pyridin-2-yl-3-(pyridin-2-ylamino)- propanolderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DE19845405C2 (de) 1998-10-02 2000-07-13 Aventis Pharma Gmbh Arylsubstituierte Propanolaminderivate und deren Verwendung
CA2431995A1 (en) 2000-12-21 2002-06-27 Aventis Pharma Deutschland Gmbh Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use
JP2005505538A (ja) * 2001-08-22 2005-02-24 アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング アリール置換プロパノールアミン誘導体と他の活性成分との組み合わせ物およびその使用
EP1553075B1 (en) 2002-10-03 2013-08-14 Ono Pharmaceutical Co., Ltd. Lpa receptor antagonists
GB0307918D0 (en) 2003-04-05 2003-05-14 Astrazeneca Ab Therapeutic use
TW200521108A (en) 2003-12-19 2005-07-01 Ono Pharmaceutical Co Compounds having lysophosphatidic acid receptor(LPA)-antagonizing effect and their use
CN1869002A (zh) * 2005-05-27 2006-11-29 中国科学院上海药物研究所 一类非甾体雄激素受体调节剂、其制备方法和用途
PL2848610T3 (pl) * 2006-11-15 2018-01-31 Ym Biosciences Australia Pty Inhibitory aktywności kinazy
EP4137137A1 (en) 2010-05-26 2023-02-22 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
EA038594B1 (ru) 2011-10-28 2021-09-21 Шайр Хьюман Дженетик Терапис, Инк. Ингибиторы рециркуляции желчных кислот для лечения гиперхолемии и холестатического заболевания печени
JP6217938B2 (ja) 2011-10-28 2017-10-25 ルメナ ファーマシューティカルズ エルエルシー 小児の胆汁うっ滞性肝疾患の処置のための胆汁酸再循環阻害剤
KR20160002773A (ko) 2013-03-15 2016-01-08 루메나 파마수티컬즈, 인코포레이티드 원발성 담관염 및 염증성 장 질환 치료용 담즙산 재순환 억제제
AU2014229050A1 (en) 2013-03-15 2015-10-22 Lumena Pharmaceuticals Llc Bile acid recycling inhibitors for treatment of Barrett's esophagus and gastroesophageal reflux disease
CN105553262B (zh) * 2015-08-24 2018-02-16 苏州瑞铬优电子科技有限公司 一种提高dc/dc升压变换器转换效率的方法
EP4424363B1 (en) 2019-02-12 2026-04-29 Mirum Pharmaceuticals, Inc. Methods for increasing growth in pediatric subjects having cholestatic liver disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI892341L (fi) * 1988-06-10 1989-12-11 Hoffmann La Roche Propanolaminderivat.
US5250524A (en) * 1990-12-06 1993-10-05 Hoechst Aktiengesellschaft Bile acid derivatives, process for their preparation and use of these compounds as pharmaceuticals
DE4040026A1 (de) * 1990-12-14 1992-06-17 Bayer Ag Substituierte pyridyl-dihydroxy-heptensaeure und deren salze
GB9203347D0 (en) * 1992-02-17 1992-04-01 Wellcome Found Hypolipidaemic compounds
ES2098570T3 (es) * 1992-02-22 1997-05-01 Hoechst Ag Amidas de un acido 4-amino-2-ureido-pirimidina-5-carboxilico, procedimiento para su preparacion, medicamentos que contienen estos compuestos y su utilizacion.

Also Published As

Publication number Publication date
EP0869121A1 (de) 1998-10-07
AR011210A1 (es) 2000-08-02
CA2233925A1 (en) 1998-10-04
NZ330110A (en) 1999-03-29
HK1015789A1 (en) 1999-10-22
KR19980081055A (ko) 1998-11-25
TR199800608A2 (en) 1998-10-21
MY114944A (en) 2003-02-28
PL325699A1 (en) 1998-10-12
CZ102598A3 (cs) 1998-10-14
JPH10287651A (ja) 1998-10-27
ID20137A (id) 1998-10-08
CN1185217C (zh) 2005-01-19
IL123927A (en) 2001-01-28
HUP9800781A2 (hu) 1999-06-28
TR199800608A3 (tr) 1998-10-21
DE59811528D1 (de) 2004-07-15
HUP9800781A3 (en) 1999-07-28
ES2223091T3 (es) 2005-02-16
HU9800781D0 (en) 1998-05-28
CZ293758B6 (cs) 2004-07-14
EP0869121B1 (de) 2004-06-09
AU6062498A (en) 1998-10-08
US5874451A (en) 1999-02-23
DK0869121T3 (da) 2004-09-20
RU2198876C2 (ru) 2003-02-20
PT869121E (pt) 2004-10-29
CN1199731A (zh) 1998-11-25
JP4234805B2 (ja) 2009-03-04
ATE268758T1 (de) 2004-06-15
BR9801150A (pt) 2000-03-21

Similar Documents

Publication Publication Date Title
US5874451A (en) Propanolamine derivatives, processes for their preparation, pharmaceuticals comprising these compounds, and their use
JP3794618B2 (ja) アリール置換プロパノールアミン誘導体、その製造法、その化合物を含有する医薬およびその使用
US4358453A (en) 1,2,4-Triazolo[4,3-a]pyridines
AU760412B2 (en) Propanolamine derivatives substituted with heterocyclic compounds, methods for their production, pharmaceutical compositions containing said compounds and the use thereof
WO2000053600A1 (en) Novel piperidine derivatives
JP2007526876A (ja) Ｄｐｐ−ｉｖ阻害剤としてのヘキサヒドロピリドイソキノリン
JP2025501178A (ja) 補体因子ｂ阻害剤の塩形態、結晶形、並びにその製造方法及び使用
WO2023143402A1 (zh) 甾类化合物、其制备方法和应用
RU2234512C2 (ru) Соединенные с желчными кислотами производные пропаноламина, лекарственное средство
JPH11505217A (ja) 新規複素環の化学
JP2001501217A (ja) Ｎ―（ベンゾチアゾール―２―イル）―１―ピペリジンエタナミン誘導体、その製法および治療的応用
CN121399098A (zh) 取代的环状化合物以及治疗苯丙酮尿症和其他氨基酸尿症的方法
US4358454A (en) 1,3,4-Triazolo[1,5-a]pyridines
JP3637974B2 (ja) ピロリジン誘導体
MXPA01002783A (en) Propanolamine derivatives substituted with heterocyclic compounds, methods for their production, pharmaceutical compositions containing said compounds and the use thereof
JP2928307B2 (ja) ピロリジン誘導体
HK40088765A (en) Salt form and crystal form of complement factor b inhibitor and preparation method and use thereof
JP2510893B2 (ja) ナフチルスルホニルアルキルカルボン酸誘導体
EP0835255A1 (en) Novel substituted azacyclic compounds
JPH07179425A (ja) 新規ピリジン誘導体及びトロンボキサンａ２ 合成酵素阻害剤
HK1015789B (en) Propanolamine derivatives, processes for their preparation, pharmaceuticals comprising these compounds, and their use
JPH04275274A (ja) ３−（６−カルボキシ−３−ピリジル）アクリル酸アミド誘導体
JPS60132982A (ja) ラクトン誘導体
JPH03193756A (ja) ナフチルスルホニルアルキルカルボン酸誘導体

Legal Events

Date Code Title Description
TC Change of applicant's name (sec. 104)

Owner name: AVENTIS PHARMA DEUTSCHLAND GMBH

Free format text: FORMER NAME: HOECHST MARION ROUSSEL DEUTSCHLAND GMBH

FGA Letters patent sealed or granted (standard patent)